The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Liver Transplantation in Patients with Hepatocellular Carcinoma

간세포암 환자에서의 간이식

  • Song, Gi-Won (Department of Surgery, Division of Liver Transplantation and Hepatobiliary Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hwang, Shin (Department of Surgery, Division of Liver Transplantation and Hepatobiliary Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sung-Gyu (Department of Surgery, Division of Liver Transplantation and Hepatobiliary Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • 송기원 (울산대학교 의과대학 서울아산병원 외과학교실 간이식 및 간담도외과) ;
  • 황신 (울산대학교 의과대학 서울아산병원 외과학교실 간이식 및 간담도외과) ;
  • 이승규 (울산대학교 의과대학 서울아산병원 외과학교실 간이식 및 간담도외과)
  • Published : 2010.06.25
⟨ Previous Next ⟩

Abstract

Hepatocellular carcinoma (HCC) is the third most common malignancy, with a new incidence of more than 11,000 cases per year and the second most common cause of malignancy-related death in Korean males. In Korea, more than 80% of all HCCs have developed from hepatitis B virus (HBV)-related cirrhotic livers. Liver transplantation (LT) is the only treatment that offers a chance of cure for HCC and the underlying liver cirrhosis simultaneously, but the availability of liver grafts and the aggressiveness of tumor recurrence are critical limiting factors of LT for HCC patients. The serious shortage of deceased-donors on strong demand for LT leads to the development of living-donor LT (LDLT) as a practical alternative replacing deceased-donor LT. Considering that HCC recurrence is the most common cause of posttransplant patient death, recipient candidates should be prudently selected through objectively established criteria. Uniquely, some Asian major LDLT centers challenged the Milan criteria, accepting a much higher number of HCC nodules instead of tumor size expansion. The eligibility criteria of LDLT for HCC are likely to be expanded more than before, but it still requires further qualified risk-benefit analyses. The development of new effective treatment modalities for HCC recurrence will reasonably expand the selection criteria further wide without the expense of recurrence rate. This article is mainly focused on the role of LT for HCC and discussed on the validity of currently available indication criteria.

Keywords

References

  1. van der Putten AB, Bijleveld CM, Slooff MJ, Wesenhagen H, Gips CH. Selection criteria and decisions in 375 patients with liver disease, considered for liver transplantation during 1977-1985. Liver 1987;7:84-90.
  2. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988;207:373-379. https://doi.org/10.1097/00000658-198804000-00002
  3. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151. https://doi.org/10.1097/00000658-199308000-00005
  4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699. https://doi.org/10.1056/NEJM199603143341104
  5. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Trasnpl 2002;8:765-774. https://doi.org/10.1053/jlts.2002.34892
  6. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935-945. https://doi.org/10.1002/lt.21445
  7. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007;25:313-319. https://doi.org/10.1159/000106911
  8. Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver trnasplantation for hepatocellular carcinoma in patients who do not meet Milan criteria. Dig Dis 2007;25:329-333. https://doi.org/10.1159/000106913
  9. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637-1644. https://doi.org/10.1002/lt.21281
  10. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007;25:310-312. https://doi.org/10.1159/000106910
  11. Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007;83:893-899. https://doi.org/10.1097/01.tp.0000259015.46798.ec
  12. Lee SG, Ahn CS, Ha TY, et al. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Surg 2009 [Epub ahead of print].
  13. Moon DB, Lee SG. Liver transplantation. Gut and liver 2009;3:145-165. https://doi.org/10.5009/gnl.2009.3.3.145
  14. Moon DB, Lee SG, Hwang S. Liver transplantation for hepatocellular carcinoma: single nodule with Child-Pugh class A sized less than 3 cm. Dig Dis 2007;25:320-328. https://doi.org/10.1159/000106912
  15. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patient hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239:142-149. https://doi.org/10.1097/01.sla.0000109022.32391.eb
  16. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation. Liver Transpl 2004;10:440-447. https://doi.org/10.1002/lt.20097
  17. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007;94:78-86. https://doi.org/10.1002/bjs.5528
  18. Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living donor liver transplantation? -no, never. J Hepatol 2005;43:573-577. https://doi.org/10.1016/j.jhep.2005.07.017
  19. Marcos A, Fisher RA, Ham JM, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000;69:1375-1379. https://doi.org/10.1097/00007890-200004150-00028
  20. Drixler TA, Vogten MJ, Ritchie ED, et al. Liver regeneration is anangiogenesis-associated phenomenon. Ann Surg 2002;236:703-712. https://doi.org/10.1097/00000658-200212000-00002
  21. Todo S, Furukawa H. The Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-459. https://doi.org/10.1097/01.sla.0000137129.98894.42
  22. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-1272. https://doi.org/10.1002/lt.20549
  23. Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role. Eastern and western perspectives. J Hepatobiliary Pancreat Surg 2009 (Epub ahead of print)
  24. Yao FY, Ferrel L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403. https://doi.org/10.1053/jhep.2001.24563
  25. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from waiting list. Liver Transpl 2002;8:873-883. https://doi.org/10.1053/jlts.2002.34923
  26. Furukawa H, Shimamura T, Suzuki T, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Surg 2009 [Epub ahead of print].
  27. Trotter JF, Adam R, Lo CM, Kenison J. Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl 2006;12:1485-1488. https://doi.org/10.1002/lt.20875
  28. Lo CM, Fan ST, Liu CL, et al. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg 2004;240:151-158. https://doi.org/10.1097/01.sla.0000129340.05238.a0
  29. Hwang S, Lee SG, Lee YJ, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006;12:920-927. https://doi.org/10.1002/lt.20734
  30. Marsh JW, Gray E, Ness R, Starzl TE. Complications of right lobe living donor liver transplantation. J Hepatol 2009;51:715-724. https://doi.org/10.1016/j.jhep.2009.04.023
  31. Bruix J, Fuster J, Llovet JM. Liver transplantation for heptocellular carcinoma: foucault pendulum versus evidence-based decision. Liver Transpl 2003;9:700-702. https://doi.org/10.1053/jlts.2003.50124
  32. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment for moderately and well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159. https://doi.org/10.1097/01.sla.0000109146.72827.76
  33. Marshall AE, Rushbrook SM, Voeler SL, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl 2010;16:279-288. https://doi.org/10.1002/lt.21993
  34. Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-258. https://doi.org/10.1016/S0168-8278(01)00108-8
  35. Perkins JD. Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver Transpl 2007;13:1603-1607. https://doi.org/10.1002/lt.21315
  36. Han K, Tzimas GN, Barkun JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007;21:39-45. https://doi.org/10.1155/2007/206383
  37. Nanashima A, Morino S, Yamaguchi H, et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatoctomy for hepatocellular carcinoma. Eur J Surg Oncol 2003;29:735-742. https://doi.org/10.1016/j.ejso.2003.08.007
  38. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of desgamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-537. https://doi.org/10.1097/TP.0b013e3181943bee
  39. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736-1741. https://doi.org/10.1007/s00268-005-0791-5
  40. Yang SH, Suh KS, Lee HW, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660. https://doi.org/10.1002/lt.20861
  41. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein level to expand candidates for living donor liver transplantation in hepatocellular carcinoma. Surgery 2007;141:598-609. https://doi.org/10.1016/j.surg.2006.11.006
  42. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
  43. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-676. https://doi.org/10.1002/hep.20375
  44. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 2005;80(suppl 1):S113-S119. https://doi.org/10.1097/01.tp.0000187109.69663.93
  45. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827. https://doi.org/10.1002/hep.22412
  46. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006;19:288-294. https://doi.org/10.1111/j.1432-2277.2006.00279.x
  47. Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006;12:665-673. https://doi.org/10.1002/lt.20636
  48. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767-775. https://doi.org/10.1002/lt.20418
  49. Perez Saborido B, Meneu JC, Moreno E, et al. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005;190:383-387. https://doi.org/10.1016/j.amjsurg.2005.06.001
  50. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003;238:508-519.
  51. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver resection for hepatocellular carcinoma. Ann Surg 2003;238:885-893. https://doi.org/10.1097/01.sla.0000098621.74851.65
  52. Hwang S, Lee SG, Moon DB, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007;13:741-746. https://doi.org/10.1002/lt.21157
  53. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma aftre liver transplantation. J Clin Oncol 1999;17:324-331. https://doi.org/10.1200/JCO.1999.17.1.324
  54. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991;68:2095-2100. https://doi.org/10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y
  55. Kornberg A, Küpper B, Tannapfel A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-280. https://doi.org/10.1016/j.ejso.2009.10.001
  56. Taketomi A, Fukuhara T, Morita K, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol 2010 [Epub ahead of print].
  57. Valdivieso A, Bustamante J, Gastaca M, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010;42:660-662. https://doi.org/10.1016/j.transproceed.2010.02.014
  58. Roayaie S, Schwarts JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns of prognosis. Liver Transpl 2004:10:534-540. https://doi.org/10.1002/lt.20128
  59. Lee JO, Kim DY, Lim JH, et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009;24:800-805. https://doi.org/10.1111/j.1440-1746.2008.05672.x
  60. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005;11:497-503. https://doi.org/10.1002/lt.20391
  61. Vivarelli M, Cuccetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-862. https://doi.org/10.1097/SLA.0b013e3181896278
  62. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:715-722. https://doi.org/10.1007/s00432-008-0506-z
  63. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimusbased immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83:1162-1168. https://doi.org/10.1097/01.tp.0000262607.95372.e0

Cited by

  1. 韓国における肝移植の現状 vol.52, pp.2, 2011, https://doi.org/10.2957/kanzo.52.150
  2. Early Steroid Withdrawal Regimen Prevents New-Onset Diabetes Mellitus in Old-Age Recipients After Living Donor Liver Transplantation vol.36, pp.10, 2012, https://doi.org/10.1007/s00268-012-1661-6
  3. Living Donor Liver Transplantation in a Hepatitis B Patient with Acute on Chronic Liver Failure Accompanying Hepatocellular Carcinoma vol.39, pp.3, 2010, https://doi.org/10.12771/emj.2016.39.3.76
  4. 간이식 환자의 뇌경색에 대한 한의학적 치료 증례보고 vol.24, pp.3, 2010, https://doi.org/10.14374/hfs.2016.24.3.225